StockMacro
Company, fund or insider

Help

Menu

X4 Pharmaceuticals

$3.00 -25% in 6 monthsMarket cap $306.3M

XFOR on XNAS, Health Care, X4 Pharmaceuticals, Inc., job postings

Measures activity, not value. Not investment advice.

Revenue fell 50% to $17M while short interest reached 4.4 times its year-earlier level.

  • BadNet loss $80.5M over 12 months, while cash $187.7M exceeds $75M debt

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. The Company's clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.

Industry
Biological products, (no diagnostic substances) (Health Care)
Employees
45
Website
x4pharma.com
Listed
Nasdaq, US
Last results
5 Nov 2025
Next results
no estimate
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $2.9M, net loss $20.2M.
Quarter to 31 Dec 2021: revenue $0, net income -$30.2MQuarter to 31 Dec 2021: revenue $0, net income -$30.2MQuarter to 31 Mar 2022: revenue –, net income -$22.0MQuarter to 30 Jun 2022: revenue –, net income -$21.2MQuarter to 30 Sep 2022: revenue –, net income -$21.6MQuarter to 31 Dec 2022: revenue –, net income -$29.1MQuarter to 31 Mar 2023: revenue –, net income -$24.0MQuarter to 30 Jun 2023: revenue $0, net income -$55.7MQuarter to 30 Jun 2023: revenue $0, net income -$55.7MQuarter to 30 Sep 2023: revenue $0, net income -$2.3MQuarter to 30 Sep 2023: revenue $0, net income -$2.3MQuarter to 31 Dec 2023: revenue –, net income -$19.1MQuarter to 31 Mar 2024: revenue $0, net income -$51.8MQuarter to 31 Mar 2024: revenue $0, net income -$51.8MQuarter to 30 Jun 2024: revenue $700K, net income $90.8MQuarter to 30 Jun 2024: revenue $700K, net income $90.8MQuarter to 30 Sep 2024: revenue $560K, net income -$36.7MQuarter to 30 Sep 2024: revenue $560K, net income -$36.7MQuarter to 31 Dec 2024: revenue $1.4M, net income -$39.8MQuarter to 31 Dec 2024: revenue $1.4M, net income -$39.8MQuarter to 31 Mar 2025: revenue $28.8M, net income $282KQuarter to 31 Mar 2025: revenue $28.8M, net income $282KQuarter to 30 Jun 2025: revenue $2.0M, net income -$25.7MQuarter to 30 Jun 2025: revenue $2.0M, net income -$25.7MQuarter to 30 Sep 2025: revenue $1.8M, net income -$29.8MQuarter to 30 Sep 2025: revenue $1.8M, net income -$29.8MQuarter to 31 Dec 2025: revenue $2.6M, net income -$23.9MQuarter to 31 Dec 2025: revenue $2.6M, net income -$23.9MQuarter to 31 Mar 2026: revenue $2.7M, net income -$20.2MQuarter to 31 Mar 2026: revenue $2.7M, net income -$20.2MQuarter to 30 Jun 2026: revenue $8.8M, net income -$16.2MQuarter to 30 Jun 2026: revenue $8.8M, net income -$16.2MQuarter to 30 Sep 2026: revenue $2.9M, net income -$20.2MQuarter to 30 Sep 2026: revenue $2.9M, net income -$20.2M
31 Dec 2021RevenueNet incomeNet losstallest bar $90.8M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$2.9M-$20.2M
30 Jun 2026$8.8M-$16.2M
31 Mar 2026$2.7M-$20.2M
31 Dec 2025$2.6M-$23.9M
30 Sep 2025$1.8M-$29.8M
30 Jun 2025$2.0M-$25.7M
31 Mar 2025$28.8M$282K
31 Dec 2024$1.4M-$39.8M
30 Sep 2024$560K-$36.7M
30 Jun 2024$700K$90.8M
31 Mar 2024$0-$51.8M
31 Dec 2023–-$19.1M
30 Sep 2023$0-$2.3M
30 Jun 2023$0-$55.7M
31 Mar 2023–-$24.0M
31 Dec 2022–-$29.1M
30 Sep 2022–-$21.6M
30 Jun 2022–-$21.2M
31 Mar 2022–-$22.0M
31 Dec 2021$0-$30.2M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $17.0M $34.0M
Revenue growthRevenue of the last 12 months compared with the 12 months before. -50% +8.2%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$80.5M -$95.1M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). – –
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. 81.8% 83.2% 70.4%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. -474% -291% -98.6%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. -475% -280% -47.8%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. -80.3% -58.2%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. – -$103.1M
CashCash, cash equivalents and short-term investments on the latest balance sheet. $187.7M $122.2M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $75.0M $75.0M
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). -$112.7M (net cash) -$47.2M
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 0.54 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $1.36
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 21.6
P/SPrice to sales: market cap divided by revenue of the last 12 months. 18.1 8.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. 11.4 6.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 2.2 2.0

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
X4 PharmaceuticalsXFOR (this company) $306.3Mloss18.1-50%-475%
TRex BioTRXB $297.0M––––
C4 TherapeuticsCCCC $325.7Mloss10.1+7.2%-282%
Precision BioSciencesDTIL $282.5Mloss6.3+6353%-85.6%
AgenusAGEN $270.1M8.82.0+25%23.0%
AlectorALEC $347.6M8.42.0+151%23.9%

Insider buy/sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

-$22K

bought $12K, sold $34K

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

+6.8%

94 13F filers vs 88

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

over 100%

108.1M shares held by 13F filers (30 Sep 2026) of 102.1M outstanding (2 Nov 2026); above 100%: the share count is probably stale

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

7.8%

8.0M shares sold short (30 Oct 2026) of 102.1M outstanding (2 Nov 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

10.9

8.0M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

+6.5%

7.5M shares sold short in the report before, 8.0M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

39%

39% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 50%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

2

Tracked since 21 Nov 2026

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

Tracking started 21 Nov 2026; the change shows after 30 days.

News Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

7

7 articles in the last 7 days; its usual week has 0.5 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

–

7 articles in the last 7 days; its usual week has 0.5: fewer than one, so there is nothing to compare with.

Unusual now sharp changes in the last 90 days, compared with its own past

  • Short interest 8.2M, 4.4× a year earlier

Price $3.00 on 20 Nov 2026, -19% over 12 months (12-month range $2.45 to $4.67)

  • Sharp change
  • 8-K and other filings
Insider net buying (open market). Insiders sold a net $451K in the last 12 months (the 12 months before: $175K).
Revenue per quarter. Revenue $2.9M in the latest quarter, +63% on a year earlier.
Capital spending per quarter. Capital spending $0 in the latest quarter.
Institutional holders (13F filers). 94 13F filers reported holding it in the latest 13F quarter, +141% on a year earlier.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: h-1b/e-3 applications certified, federal obligations, lobbying spend, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
17 Nov 2026Sharp changeShort interest spike: short interest spike, 8.0M vs usual 3.4M (2026-10-30); 5.3x the same period a year earlier
27 Oct 2026Sharp changeShort interest spike: short interest spike, 7.5M vs usual 3.3M (2026-10-15); 4.2x the same period a year earlier
13 Oct 2026Sharp changeShort interest spike: short interest spike, 7.6M vs usual 3.2M (2026-09-30); 3.7x the same period a year earlier
8 Oct 20268-K and other filingsA major agreement ended
29 Sep 2026Sharp changeShort interest spike: short interest spike, 8.2M vs usual 3.1M (2026-09-15); 4.4x the same period a year earlier
15 Sep 2026Sharp changeShort interest spike: short interest spike, 7.2M vs usual 3.1M (2026-08-31); 4.6x the same period a year earlier
1 Sep 2026Sharp changeShort interest spike: short interest spike, 7.2M vs usual 3.1M (2026-08-14); 2.9x the same period a year earlier
18 Aug 2026Sharp changeShort interest spike: short interest spike, 7.3M vs usual 3.1M (2026-07-31); 7.1x the same period a year earlier
1 Jul 20268-K and other filingsDirector or officer change
12 May 20268-K and other filingsDirector or officer change
12 May 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
17 Feb 2026Sharp changeMany funds opening a new position: many funds opening a new position, 36 vs usual 11 (2025-12-31); 3.3x the same period a year earlier
17 Sep 20258-K and other filingsDirector or officer change
17 Sep 20258-K and other filingsRestructuring costs announced
25 Aug 20258-K and other filingsPrivate placement of securities (Form D)
25 Aug 20258-K and other filingsDirector or officer change
12 Aug 20258-K and other filingsDirector or officer change
12 Aug 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
6 May 2025Sharp changeQuarterly revenue change: quarterly revenue change, 28.8M vs usual 280K (2025-03-31)
6 Feb 20258-K and other filingsRestructuring costs announced
16 Aug 20248-K and other filingsDelisting notice or listing transfer
30 Jul 2024Sharp changeShort interest spike: short interest spike, 16.5M vs usual 12.0M (2024-07-15); 1.2x the same period a year earlier
9 May 20248-K and other filingsDirector or officer change
9 May 20248-K and other filingsCompleted an acquisition or asset sale
9 May 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
14 Nov 20238-K and other filingsDelisting notice or listing transfer
31 Oct 2023Sharp changeShort interest spike: short interest spike, 10.9M vs usual 2.4M (2023-10-13); 6.6x the same period a year earlier
18 Oct 20238-K and other filingsDirector or officer change
18 Oct 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
17 Oct 2023Sharp changeShort interest spike: short interest spike, 10.6M vs usual 1.9M (2023-09-29); 5.9x the same period a year earlier
3 Oct 2023Sharp changeShort interest spike: short interest spike, 10.9M vs usual 1.8M (2023-09-15); 22.4x the same period a year earlier
19 Sep 2023Sharp changeShort interest spike: short interest spike, 10.3M vs usual 1.7M (2023-08-31); 18.8x the same period a year earlier
29 Aug 2023Sharp changeShort interest spike: short interest spike, 11.0M vs usual 1.6M (2023-08-15); 8.6x the same period a year earlier
15 Aug 2023Sharp changeMany funds opening a new position: many funds opening a new position, 42 vs usual 10 (2023-06-30); 10.5x the same period a year earlier
15 Aug 2023Sharp changeShort interest spike: short interest spike, 12.0M vs usual 1.6M (2023-07-31); 17.9x the same period a year earlier
1 Aug 2023Sharp changeShort interest spike: short interest spike, 13.6M vs usual 1.6M (2023-07-14); 23.0x the same period a year earlier
18 Jul 2023Sharp changeShort interest spike: short interest spike, 14.4M vs usual 1.5M (2023-06-30); 24.1x the same period a year earlier
4 Jul 2023Sharp changeShort interest spike: short interest spike, 9.1M vs usual 1.4M (2023-06-15); 13.9x the same period a year earlier
13 Jun 2023Sharp changeShort interest spike: short interest spike, 8.5M vs usual 1.3M (2023-05-31); 13.1x the same period a year earlier
1 Jun 20238-K and other filingsPrivate placement of securities (Form D)
4 May 20238-K and other filingsCompleted an acquisition or asset sale
17 Jan 2023Sharp changeShort interest spike: short interest spike, 1.6M vs usual 627K (2022-12-30); 3.8x the same period a year earlier
3 Jan 2023Sharp changeShort interest spike: short interest spike, 1.3M vs usual 616K (2022-12-15); 3.2x the same period a year earlier
23 Dec 20228-K and other filingsDirector or officer change
13 Dec 2022Sharp changeShort interest spike: short interest spike, 1.5M vs usual 606K (2022-11-30); 5.5x the same period a year earlier
29 Nov 2022Sharp changeShort interest spike: short interest spike, 1.5M vs usual 593K (2022-11-15); 6.5x the same period a year earlier
15 Nov 2022Sharp changeShort interest spike: short interest spike, 1.6M vs usual 576K (2022-10-31); 6.7x the same period a year earlier
9 Nov 20228-K and other filingsDirector or officer change
9 Nov 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
1 Nov 2022Sharp changeShort interest spike: short interest spike, 1.6M vs usual 556K (2022-10-14); 6.3x the same period a year earlier
18 Oct 2022Sharp changeShort interest spike: short interest spike, 1.8M vs usual 546K (2022-09-30); 9.7x the same period a year earlier
30 Aug 2022Sharp changeShort interest spike: short interest spike, 1.3M vs usual 494K (2022-08-15); 3.1x the same period a year earlier
29 Jul 20228-K and other filingsDirector or officer change
29 Jul 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
19 Jul 20228-K and other filingsPrivate placement of securities (Form D)
14 Jan 20228-K and other filingsA major agreement ended
Insider net buying (open market)
Month from 1 Feb 2022: $0 published
Month from 1 Jun 2022: -$8K published
Month from 1 Jul 2022: $0 published
Month from 1 Aug 2022: $0 published
Month from 1 Feb 2023: -$51K published
Month from 1 Mar 2023: -$115K published
Month from 1 Jun 2023: -$66K published
Month from 1 Jul 2023: -$6K published
Month from 1 Aug 2023: -$108K published
Month from 1 Sep 2023: -$3K published
Month from 1 Nov 2023: -$456K published
Month from 1 Feb 2024: -$54K published
Month from 1 Mar 2024: -$116K published
Month from 1 Sep 2024: -$2K published
Month from 1 Oct 2024: -$365K published
Month from 1 Nov 2024: -$12K published
Month from 1 Jan 2025: -$96K published
Month from 1 Feb 2025: $19K published
Month from 1 May 2025: $3K published
Month from 1 Oct 2025: $250K published
Month from 1 May 2026: -$73K published
Month from 1 Jul 2026: -$36K published
Month from 1 Aug 2026: -$320K published
Month from 1 Oct 2026: -$22K published
Revenue per quarter
Quarter ended 31 Dec 2021: $0; public on 18 Mar 2022
Quarter ended 30 Jun 2023: $0; public on 9 Aug 2024
Quarter ended 30 Sep 2023: $0; public on 14 Nov 2024
Quarter ended 31 Mar 2024: $0; public on 2 May 2025
Quarter ended 30 Jun 2024: $700K; public on 9 Aug 2024
Quarter ended 30 Sep 2024: $560K; public on 14 Nov 2024
Quarter ended 31 Dec 2024: $1.4M; public on 27 Mar 2025
Quarter ended 31 Mar 2025: $28.8M; public on 2 May 2025
Quarter ended 30 Jun 2025: $2.0M, +182% on a year earlier; public on 9 Aug 2025
Quarter ended 30 Sep 2025: $1.8M, +215% on a year earlier; public on 6 Nov 2025
Quarter ended 31 Dec 2025: $2.6M, +79% on a year earlier; public on 18 Mar 2026
Quarter ended 31 Mar 2026: $2.7M, -91% on a year earlier; public on 7 May 2026
Quarter ended 30 Jun 2026: $8.8M, +346% on a year earlier; public on 7 Aug 2026
Quarter ended 30 Sep 2026: $2.9M, +63% on a year earlier; public on 5 Nov 2026
Capital spending per quarter
Quarter ended 31 Dec 2021: $13K; public on 18 Mar 2022
Quarter ended 31 Mar 2022: $22K, -96% on a year earlier; public on 13 May 2022
Quarter ended 30 Jun 2022: $38K, -56% on a year earlier; public on 5 Aug 2022
Quarter ended 30 Sep 2022: $9K, -55% on a year earlier; public on 4 Nov 2022
Quarter ended 31 Dec 2022: $34K, +162% on a year earlier; public on 22 Mar 2023
Quarter ended 31 Mar 2023: $9K, -59% on a year earlier; public on 5 May 2023
Quarter ended 30 Jun 2023: $8K, -79% on a year earlier; public on 11 Aug 2023
Quarter ended 30 Sep 2023: $8K, -11% on a year earlier; public on 10 Nov 2023
Quarter ended 31 Dec 2023: $35K, +2.9% on a year earlier; public on 22 Mar 2024
Quarter ended 31 Mar 2024: $59K, +556% on a year earlier; public on 8 May 2024
Quarter ended 30 Jun 2024: $134K, +1575% on a year earlier; public on 9 Aug 2024
Quarter ended 30 Sep 2024: $92K, +1050% on a year earlier; public on 14 Nov 2024
Quarter ended 31 Mar 2025: $0, -100% on a year earlier; public on 2 May 2025
Quarter ended 30 Jun 2025: $0, -100% on a year earlier; public on 9 Aug 2025
Quarter ended 30 Sep 2025: $0, -100% on a year earlier; public on 6 Nov 2025
Quarter ended 31 Dec 2025: $0; public on 18 Mar 2026
Institutional holders (13F filers)
31 Dec 2021 report: 49; public on 14 Feb 2022
31 Mar 2022 report: 50; public on 16 May 2022
30 Jun 2022 report: 49; public on 15 Aug 2022
30 Sep 2022 report: 54; public on 14 Nov 2022
31 Dec 2022 report: 52; public on 14 Feb 2023
31 Mar 2023 report: 56; public on 15 May 2023
30 Jun 2023 report: 91; public on 14 Aug 2023
30 Sep 2023 report: 85; public on 14 Nov 2023
31 Dec 2023 report: 83; public on 14 Feb 2024
31 Mar 2024 report: 94; public on 15 May 2024
30 Jun 2024 report: 96; public on 14 Aug 2024
30 Sep 2024 report: 94; public on 14 Nov 2024
31 Dec 2024 report: 89; public on 14 Feb 2025
31 Mar 2025 report: 92; public on 15 May 2025
30 Jun 2025 report: 49; public on 14 Aug 2025
30 Sep 2025 report: 39; public on 14 Nov 2025
31 Dec 2025 report: 77; public on 17 Feb 2026
31 Mar 2026 report: 83; public on 15 May 2026
30 Jun 2026 report: 88; public on 14 Aug 2026
30 Sep 2026 report: 94; public on 16 Nov 2026

What is unusual now

  • Made public in the last 90 days: it had 8.2M shares sold short in the 15 Sep 2026 report, 4.4× the same report last year; it also had 7.6M shares sold short in the 30 Sep 2026 report, 3.7× the same report last year. 6 sharp changes in all.
  • Short interest spike: had 8.2M shares sold short in the 15 Sep 2026 report, 4.4× the same report last year Public on 25 Sep 2026.
  • Insider net buying (open market): Insiders sold a net $451K in the last 12 months (the 12 months before: $175K).
  • Revenue per quarter: Revenue $2.9M in the latest quarter, +63% on a year earlier.

Latest records

The names and amounts behind the totals, newest first

Last 90 days: 1 sale, $34K; 1 purchase, $12K. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
19 Oct 2026Adam R CraigExecutive ChairmanBuy4,600$2.58$12KForm 4
5 Oct 2026David KirskeChief Financial OfficerSell11,767$2.86$34KForm 4
13 Aug 2026John VolponePresidentSell24,576$4.44$109KForm 4
13 Aug 2026Adam R CraigExecutive ChairmanSell47,436$4.44$211KForm 4
1 Jul 2026David KirskeChief Financial OfficerSell8,543$4.26$36KForm 4
13 May 2026David KirskeChief Financial OfficerSell16,961$4.29$73KForm 4
27 Oct 2025Adam R CraigExecutive ChairmanBuy86,206$2.90$250KForm 4
20 May 2025Mark BaldryChief Commercial OfficerBuy1,032$2.48$3KForm 4

94 institutions reported shares at the end of Q3 2026, 100% of the shares outstanding; 13 opened a position, 6 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
Morgan Stanley11.0M10.8%$31.9M+1.5M+16%
Empery Asset Management, LP9.7M9.52%$28.2M+2.8M+40%
Bain Capital Life Sciences Investors, LLC8.0M7.80%$23.1MNo change
Venrock Adviser, LLC7.6M7.49%$22.2M+5.7M+295%
Saturn V Capital Management LP7.4M7.21%$21.4M+393K+5.6%
Perceptive Advisors LLC7.4M7.20%$21.3M-583K-7.3%
BlackRock, Inc.5.9M5.73%$17.0M+300K+5.4%
FMR LLC (Fidelity)5.5M5.38%$15.9M-2.8M-34%
Deep Track Capital, LP4.5M4.41%$13.1M-1.4M-23%
Kalehua Capital Management LLC3.7M3.65%$10.8M-3.7M-50%

Company events

All 69 company events

In 12 months: 2 director or officer changes, 1 major agreement, 1 agreement ended. Results releases and routine reports are left out.

FiledWhat happenedSource
8 Oct 2026Signed a major agreement; A major agreement endedSame filing: took on new debt, sold shares privately8-K
1 Jul 2026Director or officer change8-K
12 May 2026Director or officer changeSame filing: shareholder vote results8-K
24 Oct 2025Signed a major agreement8-K
17 Sep 2025Director or officer change; Restructuring costs announced8-K
25 Aug 2025Director or officer change8-K
25 Aug 2025Private placement of securities (Form D)$85.0M sold of $85.0M offeredD
13 Aug 2025Signed a major agreementSame filing: sold shares privately8-K

The 5 newest of 45 articles that name the company.

Timeline

Several things at once

Two or more unrelated kinds of records unusual within 30 days

15 Aug 2023confirmed

Confirmed across sources Institutional holdings and Short interest and volume

X4 Pharmaceuticals (XFOR): saw 42 13F filers open a new position in the quarter ended 30 Jun 2023, 10× the same quarter last year, while it had 10.9M shares sold short in the 15 Sep 2023 report, 22× the same report last year. Two unrelated kinds of activity within 105 days.

  • Short interest and volume: Short interest spike, became public on 13 Jul 2023
  • Short interest and volume: Short interest spike, became public on 26 Jul 2023
  • Institutional holdings: Many funds opening a new position, became public on 14 Aug 2023
  • Short interest and volume: Short interest spike, became public on 10 Aug 2023
  • Short interest and volume: Short interest spike, became public on 25 Aug 2023
  • Short interest and volume: Short interest spike, became public on 13 Sep 2023
  • Short interest and volume: Short interest spike, became public on 27 Sep 2023
  • Short interest and volume: Short interest spike, became public on 12 Oct 2023
  • Short interest and volume: Short interest spike, became public on 25 Oct 2023
2021-06-30: 192021-09-30: 42021-12-31: 122022-03-31: 72022-06-30: 42022-09-30: 142022-12-31: 102023-03-31: 102023-06-30: 42
The quarter ended 30 Jun 2023 against the 8 quarters before it. this quarterearliernormal: 10
See the evidence (9 changes)

Short interest and volume: Short interest spike became public on 13 Jul 2023

X4 Pharmaceuticals had 14.4M shares sold short in the 30 Jun 2023 report, 24× the same report last year.

This period
14.4M (the 30 Jun 2023 report)
Normal report (median of 24 earlier)
1.5M
Typical spread (median absolute deviation)
407K
How far from its usual level
+21.3
Same report last year
597K
History used
1,568 days
2022-06-30: 597K2022-07-15: 590K2022-07-29: 671K2022-08-15: 1.3M2022-08-31: 549K2022-09-15: 487K2022-09-30: 1.8M2022-10-14: 1.6M2022-10-31: 1.6M2022-11-15: 1.5M2022-11-30: 1.5M2022-12-15: 1.3M2022-12-30: 1.6M2023-01-13: 1.3M2023-01-31: 1.1M2023-02-15: 1.0M2023-02-28: 1.3M2023-03-15: 1.7M2023-03-31: 1.9M2023-04-14: 3.5M2023-04-28: 3.0M2023-05-15: 2.9M2023-05-31: 8.5M2023-06-15: 9.1M2023-06-30: 14.4M
the 30 Jun 2023 report24 earlier reportsnormal: 1.5M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 26 Jul 2023

X4 Pharmaceuticals had 13.6M shares sold short in the 14 Jul 2023 report, 23× the same report last year.

This period
13.6M (the 14 Jul 2023 report)
Normal report (median of 24 earlier)
1.6M
Typical spread (median absolute deviation)
407K
How far from its usual level
+19.9
Same report last year
590K
History used
1,582 days
2022-07-15: 590K2022-07-29: 671K2022-08-15: 1.3M2022-08-31: 549K2022-09-15: 487K2022-09-30: 1.8M2022-10-14: 1.6M2022-10-31: 1.6M2022-11-15: 1.5M2022-11-30: 1.5M2022-12-15: 1.3M2022-12-30: 1.6M2023-01-13: 1.3M2023-01-31: 1.1M2023-02-15: 1.0M2023-02-28: 1.3M2023-03-15: 1.7M2023-03-31: 1.9M2023-04-14: 3.5M2023-04-28: 3.0M2023-05-15: 2.9M2023-05-31: 8.5M2023-06-15: 9.1M2023-06-30: 14.4M2023-07-14: 13.6M
the 14 Jul 2023 report24 earlier reportsnormal: 1.6M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Institutional holdings: Many funds opening a new position became public on 14 Aug 2023

X4 Pharmaceuticals saw 42 13F filers open a new position in the quarter ended 30 Jun 2023, 10× the same quarter last year.

This period
42 (the quarter ended 30 Jun 2023)
Normal quarter (median of 8 earlier)
10
Typical spread (median absolute deviation)
3.5
How far from its usual level
+6.2
Same quarter last year
4
History used
1,552 days
2021-06-30: 192021-09-30: 42021-12-31: 122022-03-31: 72022-06-30: 42022-09-30: 142022-12-31: 102023-03-31: 102023-06-30: 42
the quarter ended 30 Jun 20238 earlier quartersnormal: 10

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

Check it at the source: SEC Form 13F data sets.

Short interest and volume: Short interest spike became public on 10 Aug 2023

X4 Pharmaceuticals had 12.0M shares sold short in the 31 Jul 2023 report, 18× the same report last year.

This period
12.0M (the 31 Jul 2023 report)
Normal report (median of 24 earlier)
1.6M
Typical spread (median absolute deviation)
436K
How far from its usual level
+16.2
Same report last year
671K
History used
1,599 days
2022-07-29: 671K2022-08-15: 1.3M2022-08-31: 549K2022-09-15: 487K2022-09-30: 1.8M2022-10-14: 1.6M2022-10-31: 1.6M2022-11-15: 1.5M2022-11-30: 1.5M2022-12-15: 1.3M2022-12-30: 1.6M2023-01-13: 1.3M2023-01-31: 1.1M2023-02-15: 1.0M2023-02-28: 1.3M2023-03-15: 1.7M2023-03-31: 1.9M2023-04-14: 3.5M2023-04-28: 3.0M2023-05-15: 2.9M2023-05-31: 8.5M2023-06-15: 9.1M2023-06-30: 14.4M2023-07-14: 13.6M2023-07-31: 12.0M
the 31 Jul 2023 report24 earlier reportsnormal: 1.6M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 25 Aug 2023

X4 Pharmaceuticals had 11.0M shares sold short in the 15 Aug 2023 report, 8.6× the same report last year.

This period
11.0M (the 15 Aug 2023 report)
Normal report (median of 24 earlier)
1.6M
Typical spread (median absolute deviation)
467K
How far from its usual level
+13.6
Same report last year
1.3M
History used
1,614 days
2022-08-15: 1.3M2022-08-31: 549K2022-09-15: 487K2022-09-30: 1.8M2022-10-14: 1.6M2022-10-31: 1.6M2022-11-15: 1.5M2022-11-30: 1.5M2022-12-15: 1.3M2022-12-30: 1.6M2023-01-13: 1.3M2023-01-31: 1.1M2023-02-15: 1.0M2023-02-28: 1.3M2023-03-15: 1.7M2023-03-31: 1.9M2023-04-14: 3.5M2023-04-28: 3.0M2023-05-15: 2.9M2023-05-31: 8.5M2023-06-15: 9.1M2023-06-30: 14.4M2023-07-14: 13.6M2023-07-31: 12.0M2023-08-15: 11.0M
the 15 Aug 2023 report24 earlier reportsnormal: 1.6M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 13 Sep 2023

X4 Pharmaceuticals had 10.3M shares sold short in the 31 Aug 2023 report, 19× the same report last year.

This period
10.3M (the 31 Aug 2023 report)
Normal report (median of 24 earlier)
1.7M
Typical spread (median absolute deviation)
618K
How far from its usual level
+9.4
Same report last year
549K
History used
1,630 days
2022-08-31: 549K2022-09-15: 487K2022-09-30: 1.8M2022-10-14: 1.6M2022-10-31: 1.6M2022-11-15: 1.5M2022-11-30: 1.5M2022-12-15: 1.3M2022-12-30: 1.6M2023-01-13: 1.3M2023-01-31: 1.1M2023-02-15: 1.0M2023-02-28: 1.3M2023-03-15: 1.7M2023-03-31: 1.9M2023-04-14: 3.5M2023-04-28: 3.0M2023-05-15: 2.9M2023-05-31: 8.5M2023-06-15: 9.1M2023-06-30: 14.4M2023-07-14: 13.6M2023-07-31: 12.0M2023-08-15: 11.0M2023-08-31: 10.3M
the 31 Aug 2023 report24 earlier reportsnormal: 1.7M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 27 Sep 2023

X4 Pharmaceuticals had 10.9M shares sold short in the 15 Sep 2023 report, 22× the same report last year.

This period
10.9M (the 15 Sep 2023 report)
Normal report (median of 24 earlier)
1.8M
Typical spread (median absolute deviation)
700K
How far from its usual level
+8.8
Same report last year
487K
History used
1,645 days
2022-09-15: 487K2022-09-30: 1.8M2022-10-14: 1.6M2022-10-31: 1.6M2022-11-15: 1.5M2022-11-30: 1.5M2022-12-15: 1.3M2022-12-30: 1.6M2023-01-13: 1.3M2023-01-31: 1.1M2023-02-15: 1.0M2023-02-28: 1.3M2023-03-15: 1.7M2023-03-31: 1.9M2023-04-14: 3.5M2023-04-28: 3.0M2023-05-15: 2.9M2023-05-31: 8.5M2023-06-15: 9.1M2023-06-30: 14.4M2023-07-14: 13.6M2023-07-31: 12.0M2023-08-15: 11.0M2023-08-31: 10.3M2023-09-15: 10.9M
the 15 Sep 2023 report24 earlier reportsnormal: 1.8M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 12 Oct 2023

X4 Pharmaceuticals had 10.6M shares sold short in the 29 Sep 2023 report, 5.9× the same report last year.

This period
10.6M (the 29 Sep 2023 report)
Normal report (median of 24 earlier)
1.9M
Typical spread (median absolute deviation)
792K
How far from its usual level
+7.5
Same report last year
1.8M
History used
1,659 days
2022-09-30: 1.8M2022-10-14: 1.6M2022-10-31: 1.6M2022-11-15: 1.5M2022-11-30: 1.5M2022-12-15: 1.3M2022-12-30: 1.6M2023-01-13: 1.3M2023-01-31: 1.1M2023-02-15: 1.0M2023-02-28: 1.3M2023-03-15: 1.7M2023-03-31: 1.9M2023-04-14: 3.5M2023-04-28: 3.0M2023-05-15: 2.9M2023-05-31: 8.5M2023-06-15: 9.1M2023-06-30: 14.4M2023-07-14: 13.6M2023-07-31: 12.0M2023-08-15: 11.0M2023-08-31: 10.3M2023-09-15: 10.9M2023-09-29: 10.6M
the 29 Sep 2023 report24 earlier reportsnormal: 1.9M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 25 Oct 2023

X4 Pharmaceuticals had 10.9M shares sold short in the 13 Oct 2023 report, 6.6× the same report last year.

This period
10.9M (the 13 Oct 2023 report)
Normal report (median of 24 earlier)
2.4M
Typical spread (median absolute deviation)
1.2M
How far from its usual level
+4.9
Same report last year
1.6M
History used
1,673 days
2022-10-14: 1.6M2022-10-31: 1.6M2022-11-15: 1.5M2022-11-30: 1.5M2022-12-15: 1.3M2022-12-30: 1.6M2023-01-13: 1.3M2023-01-31: 1.1M2023-02-15: 1.0M2023-02-28: 1.3M2023-03-15: 1.7M2023-03-31: 1.9M2023-04-14: 3.5M2023-04-28: 3.0M2023-05-15: 2.9M2023-05-31: 8.5M2023-06-15: 9.1M2023-06-30: 14.4M2023-07-14: 13.6M2023-07-31: 12.0M2023-08-15: 11.0M2023-08-31: 10.3M2023-09-15: 10.9M2023-09-29: 10.6M2023-10-13: 10.9M
the 13 Oct 2023 report24 earlier reportsnormal: 2.4M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

Timeline

Changes and notable records, by the date each became public

  1. 11 Nov 2026Short interest and volume change

    had 8.0M shares sold short in the 30 Oct 2026 report, 5.3× the same report last year.

    Same report last year: 1.5M; its normal report is 3.4M.

    See the evidence
    This period
    8.0M (the 30 Oct 2026 report)
    Normal report (median of 24 earlier)
    3.4M
    Typical spread (median absolute deviation)
    628K
    How far from its usual level
    +4.9
    Same report last year
    1.5M
    History used
    2,786 days
    2025-10-31: 1.5M2025-11-14: 1.9M2025-11-28: 2.5M2025-12-15: 3.2M2025-12-31: 3.0M2026-01-15: 3.1M2026-01-30: 3.1M2026-02-13: 3.4M2026-02-27: 3.5M2026-03-13: 3.5M2026-03-31: 3.1M2026-04-15: 3.1M2026-04-30: 3.1M2026-05-15: 2.9M2026-05-29: 3.4M2026-06-15: 4.2M2026-06-30: 5.5M2026-07-15: 6.5M2026-07-31: 7.3M2026-08-14: 7.2M2026-08-31: 7.2M2026-09-15: 8.2M2026-09-30: 7.6M2026-10-15: 7.5M2026-10-30: 8.0M
    the 30 Oct 2026 report24 earlier reportsnormal: 3.4M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  2. 27 Oct 2026Short interest and volume change

    had 7.5M shares sold short in the 15 Oct 2026 report, 4.2× the same report last year.

    Same report last year: 1.8M; its normal report is 3.3M.

    See the evidence
    This period
    7.5M (the 15 Oct 2026 report)
    Normal report (median of 24 earlier)
    3.3M
    Typical spread (median absolute deviation)
    561K
    How far from its usual level
    +5.1
    Same report last year
    1.8M
    History used
    2,771 days
    2025-10-15: 1.8M2025-10-31: 1.5M2025-11-14: 1.9M2025-11-28: 2.5M2025-12-15: 3.2M2025-12-31: 3.0M2026-01-15: 3.1M2026-01-30: 3.1M2026-02-13: 3.4M2026-02-27: 3.5M2026-03-13: 3.5M2026-03-31: 3.1M2026-04-15: 3.1M2026-04-30: 3.1M2026-05-15: 2.9M2026-05-29: 3.4M2026-06-15: 4.2M2026-06-30: 5.5M2026-07-15: 6.5M2026-07-31: 7.3M2026-08-14: 7.2M2026-08-31: 7.2M2026-09-15: 8.2M2026-09-30: 7.6M2026-10-15: 7.5M
    the 15 Oct 2026 report24 earlier reportsnormal: 3.3M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  3. 19 Oct 2026Insiders record

    Craig Adam R (Executive Chairman) bought 4,600 shares of XFOR ($11,884)

  4. 10 Oct 2026Short interest and volume change

    had 7.6M shares sold short in the 30 Sep 2026 report, 3.7× the same report last year.

    Same report last year: 2.0M; its normal report is 3.2M.

    See the evidence
    This period
    7.6M (the 30 Sep 2026 report)
    Normal report (median of 24 earlier)
    3.2M
    Typical spread (median absolute deviation)
    508K
    How far from its usual level
    +5.9
    Same report last year
    2.0M
    History used
    2,756 days
    2025-09-30: 2.0M2025-10-15: 1.8M2025-10-31: 1.5M2025-11-14: 1.9M2025-11-28: 2.5M2025-12-15: 3.2M2025-12-31: 3.0M2026-01-15: 3.1M2026-01-30: 3.1M2026-02-13: 3.4M2026-02-27: 3.5M2026-03-13: 3.5M2026-03-31: 3.1M2026-04-15: 3.1M2026-04-30: 3.1M2026-05-15: 2.9M2026-05-29: 3.4M2026-06-15: 4.2M2026-06-30: 5.5M2026-07-15: 6.5M2026-07-31: 7.3M2026-08-14: 7.2M2026-08-31: 7.2M2026-09-15: 8.2M2026-09-30: 7.6M
    the 30 Sep 2026 report24 earlier reportsnormal: 3.2M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  5. 8 Oct 2026Filings record

    A major agreement ended

  6. 25 Sep 2026Short interest and volume change

    had 8.2M shares sold short in the 15 Sep 2026 report, 4.4× the same report last year.

    Same report last year: 1.9M; its normal report is 3.1M.

    See the evidence
    This period
    8.2M (the 15 Sep 2026 report)
    Normal report (median of 24 earlier)
    3.1M
    Typical spread (median absolute deviation)
    508K
    How far from its usual level
    +6.8
    Same report last year
    1.9M
    History used
    2,741 days
    2025-09-15: 1.9M2025-09-30: 2.0M2025-10-15: 1.8M2025-10-31: 1.5M2025-11-14: 1.9M2025-11-28: 2.5M2025-12-15: 3.2M2025-12-31: 3.0M2026-01-15: 3.1M2026-01-30: 3.1M2026-02-13: 3.4M2026-02-27: 3.5M2026-03-13: 3.5M2026-03-31: 3.1M2026-04-15: 3.1M2026-04-30: 3.1M2026-05-15: 2.9M2026-05-29: 3.4M2026-06-15: 4.2M2026-06-30: 5.5M2026-07-15: 6.5M2026-07-31: 7.3M2026-08-14: 7.2M2026-08-31: 7.2M2026-09-15: 8.2M
    the 15 Sep 2026 report24 earlier reportsnormal: 3.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  7. 11 Sep 2026Short interest and volume change

    had 7.2M shares sold short in the 31 Aug 2026 report, 4.6× the same report last year.

    Same report last year: 1.6M; its normal report is 3.1M.

    See the evidence
    This period
    7.2M (the 31 Aug 2026 report)
    Normal report (median of 24 earlier)
    3.1M
    Typical spread (median absolute deviation)
    508K
    How far from its usual level
    +5.4
    Same report last year
    1.6M
    History used
    2,726 days
    2025-08-29: 1.6M2025-09-15: 1.9M2025-09-30: 2.0M2025-10-15: 1.8M2025-10-31: 1.5M2025-11-14: 1.9M2025-11-28: 2.5M2025-12-15: 3.2M2025-12-31: 3.0M2026-01-15: 3.1M2026-01-30: 3.1M2026-02-13: 3.4M2026-02-27: 3.5M2026-03-13: 3.5M2026-03-31: 3.1M2026-04-15: 3.1M2026-04-30: 3.1M2026-05-15: 2.9M2026-05-29: 3.4M2026-06-15: 4.2M2026-06-30: 5.5M2026-07-15: 6.5M2026-07-31: 7.3M2026-08-14: 7.2M2026-08-31: 7.2M
    the 31 Aug 2026 report24 earlier reportsnormal: 3.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  8. 26 Aug 2026Short interest and volume change

    had 7.2M shares sold short in the 14 Aug 2026 report, 2.9× the same report last year.

    Same report last year: 2.5M; its normal report is 3.1M.

    See the evidence
    This period
    7.2M (the 14 Aug 2026 report)
    Normal report (median of 24 earlier)
    3.1M
    Typical spread (median absolute deviation)
    508K
    How far from its usual level
    +5.4
    Same report last year
    2.5M
    History used
    2,709 days
    2025-08-15: 2.5M2025-08-29: 1.6M2025-09-15: 1.9M2025-09-30: 2.0M2025-10-15: 1.8M2025-10-31: 1.5M2025-11-14: 1.9M2025-11-28: 2.5M2025-12-15: 3.2M2025-12-31: 3.0M2026-01-15: 3.1M2026-01-30: 3.1M2026-02-13: 3.4M2026-02-27: 3.5M2026-03-13: 3.5M2026-03-31: 3.1M2026-04-15: 3.1M2026-04-30: 3.1M2026-05-15: 2.9M2026-05-29: 3.4M2026-06-15: 4.2M2026-06-30: 5.5M2026-07-15: 6.5M2026-07-31: 7.3M2026-08-14: 7.2M
    the 14 Aug 2026 report24 earlier reportsnormal: 3.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  9. 12 Aug 2026Short interest and volume change

    had 7.3M shares sold short in the 31 Jul 2026 report, 7.1× the same report last year.

    Same report last year: 1.0M; its normal report is 3.1M.

    See the evidence
    This period
    7.3M (the 31 Jul 2026 report)
    Normal report (median of 24 earlier)
    3.1M
    Typical spread (median absolute deviation)
    508K
    How far from its usual level
    +5.6
    Same report last year
    1.0M
    History used
    2,695 days
    2025-07-31: 1.0M2025-08-15: 2.5M2025-08-29: 1.6M2025-09-15: 1.9M2025-09-30: 2.0M2025-10-15: 1.8M2025-10-31: 1.5M2025-11-14: 1.9M2025-11-28: 2.5M2025-12-15: 3.2M2025-12-31: 3.0M2026-01-15: 3.1M2026-01-30: 3.1M2026-02-13: 3.4M2026-02-27: 3.5M2026-03-13: 3.5M2026-03-31: 3.1M2026-04-15: 3.1M2026-04-30: 3.1M2026-05-15: 2.9M2026-05-29: 3.4M2026-06-15: 4.2M2026-06-30: 5.5M2026-07-15: 6.5M2026-07-31: 7.3M
    the 31 Jul 2026 report24 earlier reportsnormal: 3.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  10. 1 Jul 2026Filings record

    Director or officer change

  11. 12 May 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  12. 12 May 2026Filings record

    Director or officer change

  13. 17 Feb 2026Institutional holdings change

    saw 36 13F filers open a new position in the quarter ended 31 Dec 2025, 3.3× the same quarter last year.

    Same quarter last year: 11; its normal quarter is 11.

    See the evidence
    This period
    36 (the quarter ended 31 Dec 2025)
    Normal quarter (median of 8 earlier)
    11
    Typical spread (median absolute deviation)
    1.5
    How far from its usual level
    +8.3
    Same quarter last year
    11
    History used
    2,467 days
    2023-12-31: 102024-03-31: 162024-06-30: 152024-09-30: 92024-12-31: 112025-03-31: 132025-06-30: 102025-09-30: 112025-12-31: 36
    the quarter ended 31 Dec 20258 earlier quartersnormal: 11

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  14. 28 Oct 2025Insiders record

    Craig Adam R (Executive Chairman) bought 86,206 shares of XFOR ($249,997) (dated 27 Oct 2025)

  15. 17 Sep 2025Filings record

    Director or officer change

  16. 17 Sep 2025Filings record

    Restructuring costs announced

  17. 25 Aug 2025Filings record

    Private placement of securities (Form D)

  18. 25 Aug 2025Filings record

    Director or officer change

  19. 12 Aug 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  20. 12 Aug 2025Filings record

    Director or officer change

  21. 21 May 2025Insiders record

    Baldry Mark (Chief Commercial Officer) bought 1,032 shares of XFOR ($2,559) (dated 20 May 2025)

  22. 6 May 2025Financials change

    reported revenue of $28.8M for the quarter ended 31 Mar 2025, against none in the same quarter last year.

    See the evidence
    This period
    $28.8M (the quarter ended 31 Mar 2025)
    Normal quarter (median of 6 earlier)
    $280K
    Typical spread (median absolute deviation)
    $280K
    How far from its usual level
    +28.5
    Same quarter last year
    $0
    History used
    2,282 days
    2023-06-30: $02023-09-30: $02024-03-31: $02024-06-30: $700K2024-09-30: $560K2024-12-31: $1.4M2025-03-31: $28.8M
    the quarter ended 31 Mar 20256 earlier quartersnormal: $280K

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  23. 15 Feb 2025Insiders record

    Baldry Mark (Chief Commercial Officer) bought 35,050 shares of XFOR ($19,277) (dated 14 Feb 2025)

  24. 6 Feb 2025Filings record

    Restructuring costs announced

  25. 16 Aug 2024Filings record

    Delisting notice or listing transfer

  26. 25 Jul 2024Short interest and volume change

    had 16.5M shares sold short in the 15 Jul 2024 report, 1.2× the same report last year.

    Same report last year: 13.6M; its normal report is 12.0M.

    See the evidence
    This period
    16.5M (the 15 Jul 2024 report)
    Normal report (median of 24 earlier)
    12.0M
    Typical spread (median absolute deviation)
    687K
    How far from its usual level
    +3.8
    Same report last year
    13.6M
    History used
    1,949 days
    2023-07-14: 13.6M2023-07-31: 12.0M2023-08-15: 11.0M2023-08-31: 10.3M2023-09-15: 10.9M2023-09-29: 10.6M2023-10-13: 10.9M2023-10-31: 11.5M2023-11-15: 11.5M2023-11-30: 11.4M2023-12-15: 11.7M2023-12-29: 11.6M2024-01-12: 12.0M2024-01-31: 12.8M2024-02-15: 13.2M2024-02-29: 14.4M2024-03-15: 14.2M2024-03-28: 12.3M2024-04-15: 12.3M2024-04-30: 13.2M2024-05-15: 12.2M2024-05-31: 11.9M2024-06-14: 11.9M2024-06-28: 13.9M2024-07-15: 16.5M
    the 15 Jul 2024 report24 earlier reportsnormal: 12.0M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  27. 9 May 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  28. 9 May 2024Filings record

    Director or officer change

  29. 9 May 2024Filings record

    Completed an acquisition or asset sale

  30. 14 Nov 2023Filings record

    Delisting notice or listing transfer

  31. 25 Oct 2023Short interest and volume change

    had 10.9M shares sold short in the 13 Oct 2023 report, 6.6× the same report last year.

    Same report last year: 1.6M; its normal report is 2.4M.

    See the evidence
    This period
    10.9M (the 13 Oct 2023 report)
    Normal report (median of 24 earlier)
    2.4M
    Typical spread (median absolute deviation)
    1.2M
    How far from its usual level
    +4.9
    Same report last year
    1.6M
    History used
    1,673 days
    2022-10-14: 1.6M2022-10-31: 1.6M2022-11-15: 1.5M2022-11-30: 1.5M2022-12-15: 1.3M2022-12-30: 1.6M2023-01-13: 1.3M2023-01-31: 1.1M2023-02-15: 1.0M2023-02-28: 1.3M2023-03-15: 1.7M2023-03-31: 1.9M2023-04-14: 3.5M2023-04-28: 3.0M2023-05-15: 2.9M2023-05-31: 8.5M2023-06-15: 9.1M2023-06-30: 14.4M2023-07-14: 13.6M2023-07-31: 12.0M2023-08-15: 11.0M2023-08-31: 10.3M2023-09-15: 10.9M2023-09-29: 10.6M2023-10-13: 10.9M
    the 13 Oct 2023 report24 earlier reportsnormal: 2.4M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  32. 18 Oct 2023Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  33. 18 Oct 2023Filings record

    Director or officer change

  34. 12 Oct 2023Short interest and volume change

    had 10.6M shares sold short in the 29 Sep 2023 report, 5.9× the same report last year.

    Same report last year: 1.8M; its normal report is 1.9M.

    See the evidence
    This period
    10.6M (the 29 Sep 2023 report)
    Normal report (median of 24 earlier)
    1.9M
    Typical spread (median absolute deviation)
    792K
    How far from its usual level
    +7.5
    Same report last year
    1.8M
    History used
    1,659 days
    2022-09-30: 1.8M2022-10-14: 1.6M2022-10-31: 1.6M2022-11-15: 1.5M2022-11-30: 1.5M2022-12-15: 1.3M2022-12-30: 1.6M2023-01-13: 1.3M2023-01-31: 1.1M2023-02-15: 1.0M2023-02-28: 1.3M2023-03-15: 1.7M2023-03-31: 1.9M2023-04-14: 3.5M2023-04-28: 3.0M2023-05-15: 2.9M2023-05-31: 8.5M2023-06-15: 9.1M2023-06-30: 14.4M2023-07-14: 13.6M2023-07-31: 12.0M2023-08-15: 11.0M2023-08-31: 10.3M2023-09-15: 10.9M2023-09-29: 10.6M
    the 29 Sep 2023 report24 earlier reportsnormal: 1.9M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  35. 27 Sep 2023Short interest and volume change

    had 10.9M shares sold short in the 15 Sep 2023 report, 22× the same report last year.

    Same report last year: 487K; its normal report is 1.8M.

    See the evidence
    This period
    10.9M (the 15 Sep 2023 report)
    Normal report (median of 24 earlier)
    1.8M
    Typical spread (median absolute deviation)
    700K
    How far from its usual level
    +8.8
    Same report last year
    487K
    History used
    1,645 days
    2022-09-15: 487K2022-09-30: 1.8M2022-10-14: 1.6M2022-10-31: 1.6M2022-11-15: 1.5M2022-11-30: 1.5M2022-12-15: 1.3M2022-12-30: 1.6M2023-01-13: 1.3M2023-01-31: 1.1M2023-02-15: 1.0M2023-02-28: 1.3M2023-03-15: 1.7M2023-03-31: 1.9M2023-04-14: 3.5M2023-04-28: 3.0M2023-05-15: 2.9M2023-05-31: 8.5M2023-06-15: 9.1M2023-06-30: 14.4M2023-07-14: 13.6M2023-07-31: 12.0M2023-08-15: 11.0M2023-08-31: 10.3M2023-09-15: 10.9M
    the 15 Sep 2023 report24 earlier reportsnormal: 1.8M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  36. 13 Sep 2023Short interest and volume change

    had 10.3M shares sold short in the 31 Aug 2023 report, 19× the same report last year.

    Same report last year: 549K; its normal report is 1.7M.

    See the evidence
    This period
    10.3M (the 31 Aug 2023 report)
    Normal report (median of 24 earlier)
    1.7M
    Typical spread (median absolute deviation)
    618K
    How far from its usual level
    +9.4
    Same report last year
    549K
    History used
    1,630 days
    2022-08-31: 549K2022-09-15: 487K2022-09-30: 1.8M2022-10-14: 1.6M2022-10-31: 1.6M2022-11-15: 1.5M2022-11-30: 1.5M2022-12-15: 1.3M2022-12-30: 1.6M2023-01-13: 1.3M2023-01-31: 1.1M2023-02-15: 1.0M2023-02-28: 1.3M2023-03-15: 1.7M2023-03-31: 1.9M2023-04-14: 3.5M2023-04-28: 3.0M2023-05-15: 2.9M2023-05-31: 8.5M2023-06-15: 9.1M2023-06-30: 14.4M2023-07-14: 13.6M2023-07-31: 12.0M2023-08-15: 11.0M2023-08-31: 10.3M
    the 31 Aug 2023 report24 earlier reportsnormal: 1.7M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  37. 25 Aug 2023Short interest and volume change

    had 11.0M shares sold short in the 15 Aug 2023 report, 8.6× the same report last year.

    Same report last year: 1.3M; its normal report is 1.6M.

    See the evidence
    This period
    11.0M (the 15 Aug 2023 report)
    Normal report (median of 24 earlier)
    1.6M
    Typical spread (median absolute deviation)
    467K
    How far from its usual level
    +13.6
    Same report last year
    1.3M
    History used
    1,614 days
    2022-08-15: 1.3M2022-08-31: 549K2022-09-15: 487K2022-09-30: 1.8M2022-10-14: 1.6M2022-10-31: 1.6M2022-11-15: 1.5M2022-11-30: 1.5M2022-12-15: 1.3M2022-12-30: 1.6M2023-01-13: 1.3M2023-01-31: 1.1M2023-02-15: 1.0M2023-02-28: 1.3M2023-03-15: 1.7M2023-03-31: 1.9M2023-04-14: 3.5M2023-04-28: 3.0M2023-05-15: 2.9M2023-05-31: 8.5M2023-06-15: 9.1M2023-06-30: 14.4M2023-07-14: 13.6M2023-07-31: 12.0M2023-08-15: 11.0M
    the 15 Aug 2023 report24 earlier reportsnormal: 1.6M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  38. 23 Aug 2023Insiders record

    WYZGA MICHAEL S (director) bought 25,000 shares of XFOR ($30,000) (dated 22 Aug 2023)

  39. 15 Aug 2023several at once

    saw 42 13F filers open a new position in the quarter ended 30 Jun 2023, 10× the same quarter last year, while it had 10.9M shares sold short in the 15 Sep 2023 report, 22× the same report last year. Two unrelated kinds of activity within 105 days.

    See the evidence (9 changes)

    Short interest and volume: Short interest spike became public on 13 Jul 2023

    X4 Pharmaceuticals had 14.4M shares sold short in the 30 Jun 2023 report, 24× the same report last year.

    This period
    14.4M (the 30 Jun 2023 report)
    Normal report (median of 24 earlier)
    1.5M
    Typical spread (median absolute deviation)
    407K
    How far from its usual level
    +21.3
    Same report last year
    597K
    History used
    1,568 days
    2022-06-30: 597K2022-07-15: 590K2022-07-29: 671K2022-08-15: 1.3M2022-08-31: 549K2022-09-15: 487K2022-09-30: 1.8M2022-10-14: 1.6M2022-10-31: 1.6M2022-11-15: 1.5M2022-11-30: 1.5M2022-12-15: 1.3M2022-12-30: 1.6M2023-01-13: 1.3M2023-01-31: 1.1M2023-02-15: 1.0M2023-02-28: 1.3M2023-03-15: 1.7M2023-03-31: 1.9M2023-04-14: 3.5M2023-04-28: 3.0M2023-05-15: 2.9M2023-05-31: 8.5M2023-06-15: 9.1M2023-06-30: 14.4M
    the 30 Jun 2023 report24 earlier reportsnormal: 1.5M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 26 Jul 2023

    X4 Pharmaceuticals had 13.6M shares sold short in the 14 Jul 2023 report, 23× the same report last year.

    This period
    13.6M (the 14 Jul 2023 report)
    Normal report (median of 24 earlier)
    1.6M
    Typical spread (median absolute deviation)
    407K
    How far from its usual level
    +19.9
    Same report last year
    590K
    History used
    1,582 days
    2022-07-15: 590K2022-07-29: 671K2022-08-15: 1.3M2022-08-31: 549K2022-09-15: 487K2022-09-30: 1.8M2022-10-14: 1.6M2022-10-31: 1.6M2022-11-15: 1.5M2022-11-30: 1.5M2022-12-15: 1.3M2022-12-30: 1.6M2023-01-13: 1.3M2023-01-31: 1.1M2023-02-15: 1.0M2023-02-28: 1.3M2023-03-15: 1.7M2023-03-31: 1.9M2023-04-14: 3.5M2023-04-28: 3.0M2023-05-15: 2.9M2023-05-31: 8.5M2023-06-15: 9.1M2023-06-30: 14.4M2023-07-14: 13.6M
    the 14 Jul 2023 report24 earlier reportsnormal: 1.6M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Institutional holdings: Many funds opening a new position became public on 14 Aug 2023

    X4 Pharmaceuticals saw 42 13F filers open a new position in the quarter ended 30 Jun 2023, 10× the same quarter last year.

    This period
    42 (the quarter ended 30 Jun 2023)
    Normal quarter (median of 8 earlier)
    10
    Typical spread (median absolute deviation)
    3.5
    How far from its usual level
    +6.2
    Same quarter last year
    4
    History used
    1,552 days
    2021-06-30: 192021-09-30: 42021-12-31: 122022-03-31: 72022-06-30: 42022-09-30: 142022-12-31: 102023-03-31: 102023-06-30: 42
    the quarter ended 30 Jun 20238 earlier quartersnormal: 10

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

    Short interest and volume: Short interest spike became public on 10 Aug 2023

    X4 Pharmaceuticals had 12.0M shares sold short in the 31 Jul 2023 report, 18× the same report last year.

    This period
    12.0M (the 31 Jul 2023 report)
    Normal report (median of 24 earlier)
    1.6M
    Typical spread (median absolute deviation)
    436K
    How far from its usual level
    +16.2
    Same report last year
    671K
    History used
    1,599 days
    2022-07-29: 671K2022-08-15: 1.3M2022-08-31: 549K2022-09-15: 487K2022-09-30: 1.8M2022-10-14: 1.6M2022-10-31: 1.6M2022-11-15: 1.5M2022-11-30: 1.5M2022-12-15: 1.3M2022-12-30: 1.6M2023-01-13: 1.3M2023-01-31: 1.1M2023-02-15: 1.0M2023-02-28: 1.3M2023-03-15: 1.7M2023-03-31: 1.9M2023-04-14: 3.5M2023-04-28: 3.0M2023-05-15: 2.9M2023-05-31: 8.5M2023-06-15: 9.1M2023-06-30: 14.4M2023-07-14: 13.6M2023-07-31: 12.0M
    the 31 Jul 2023 report24 earlier reportsnormal: 1.6M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 25 Aug 2023

    X4 Pharmaceuticals had 11.0M shares sold short in the 15 Aug 2023 report, 8.6× the same report last year.

    This period
    11.0M (the 15 Aug 2023 report)
    Normal report (median of 24 earlier)
    1.6M
    Typical spread (median absolute deviation)
    467K
    How far from its usual level
    +13.6
    Same report last year
    1.3M
    History used
    1,614 days
    2022-08-15: 1.3M2022-08-31: 549K2022-09-15: 487K2022-09-30: 1.8M2022-10-14: 1.6M2022-10-31: 1.6M2022-11-15: 1.5M2022-11-30: 1.5M2022-12-15: 1.3M2022-12-30: 1.6M2023-01-13: 1.3M2023-01-31: 1.1M2023-02-15: 1.0M2023-02-28: 1.3M2023-03-15: 1.7M2023-03-31: 1.9M2023-04-14: 3.5M2023-04-28: 3.0M2023-05-15: 2.9M2023-05-31: 8.5M2023-06-15: 9.1M2023-06-30: 14.4M2023-07-14: 13.6M2023-07-31: 12.0M2023-08-15: 11.0M
    the 15 Aug 2023 report24 earlier reportsnormal: 1.6M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 13 Sep 2023

    X4 Pharmaceuticals had 10.3M shares sold short in the 31 Aug 2023 report, 19× the same report last year.

    This period
    10.3M (the 31 Aug 2023 report)
    Normal report (median of 24 earlier)
    1.7M
    Typical spread (median absolute deviation)
    618K
    How far from its usual level
    +9.4
    Same report last year
    549K
    History used
    1,630 days
    2022-08-31: 549K2022-09-15: 487K2022-09-30: 1.8M2022-10-14: 1.6M2022-10-31: 1.6M2022-11-15: 1.5M2022-11-30: 1.5M2022-12-15: 1.3M2022-12-30: 1.6M2023-01-13: 1.3M2023-01-31: 1.1M2023-02-15: 1.0M2023-02-28: 1.3M2023-03-15: 1.7M2023-03-31: 1.9M2023-04-14: 3.5M2023-04-28: 3.0M2023-05-15: 2.9M2023-05-31: 8.5M2023-06-15: 9.1M2023-06-30: 14.4M2023-07-14: 13.6M2023-07-31: 12.0M2023-08-15: 11.0M2023-08-31: 10.3M
    the 31 Aug 2023 report24 earlier reportsnormal: 1.7M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 27 Sep 2023

    X4 Pharmaceuticals had 10.9M shares sold short in the 15 Sep 2023 report, 22× the same report last year.

    This period
    10.9M (the 15 Sep 2023 report)
    Normal report (median of 24 earlier)
    1.8M
    Typical spread (median absolute deviation)
    700K
    How far from its usual level
    +8.8
    Same report last year
    487K
    History used
    1,645 days
    2022-09-15: 487K2022-09-30: 1.8M2022-10-14: 1.6M2022-10-31: 1.6M2022-11-15: 1.5M2022-11-30: 1.5M2022-12-15: 1.3M2022-12-30: 1.6M2023-01-13: 1.3M2023-01-31: 1.1M2023-02-15: 1.0M2023-02-28: 1.3M2023-03-15: 1.7M2023-03-31: 1.9M2023-04-14: 3.5M2023-04-28: 3.0M2023-05-15: 2.9M2023-05-31: 8.5M2023-06-15: 9.1M2023-06-30: 14.4M2023-07-14: 13.6M2023-07-31: 12.0M2023-08-15: 11.0M2023-08-31: 10.3M2023-09-15: 10.9M
    the 15 Sep 2023 report24 earlier reportsnormal: 1.8M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 12 Oct 2023

    X4 Pharmaceuticals had 10.6M shares sold short in the 29 Sep 2023 report, 5.9× the same report last year.

    This period
    10.6M (the 29 Sep 2023 report)
    Normal report (median of 24 earlier)
    1.9M
    Typical spread (median absolute deviation)
    792K
    How far from its usual level
    +7.5
    Same report last year
    1.8M
    History used
    1,659 days
    2022-09-30: 1.8M2022-10-14: 1.6M2022-10-31: 1.6M2022-11-15: 1.5M2022-11-30: 1.5M2022-12-15: 1.3M2022-12-30: 1.6M2023-01-13: 1.3M2023-01-31: 1.1M2023-02-15: 1.0M2023-02-28: 1.3M2023-03-15: 1.7M2023-03-31: 1.9M2023-04-14: 3.5M2023-04-28: 3.0M2023-05-15: 2.9M2023-05-31: 8.5M2023-06-15: 9.1M2023-06-30: 14.4M2023-07-14: 13.6M2023-07-31: 12.0M2023-08-15: 11.0M2023-08-31: 10.3M2023-09-15: 10.9M2023-09-29: 10.6M
    the 29 Sep 2023 report24 earlier reportsnormal: 1.9M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 25 Oct 2023

    X4 Pharmaceuticals had 10.9M shares sold short in the 13 Oct 2023 report, 6.6× the same report last year.

    This period
    10.9M (the 13 Oct 2023 report)
    Normal report (median of 24 earlier)
    2.4M
    Typical spread (median absolute deviation)
    1.2M
    How far from its usual level
    +4.9
    Same report last year
    1.6M
    History used
    1,673 days
    2022-10-14: 1.6M2022-10-31: 1.6M2022-11-15: 1.5M2022-11-30: 1.5M2022-12-15: 1.3M2022-12-30: 1.6M2023-01-13: 1.3M2023-01-31: 1.1M2023-02-15: 1.0M2023-02-28: 1.3M2023-03-15: 1.7M2023-03-31: 1.9M2023-04-14: 3.5M2023-04-28: 3.0M2023-05-15: 2.9M2023-05-31: 8.5M2023-06-15: 9.1M2023-06-30: 14.4M2023-07-14: 13.6M2023-07-31: 12.0M2023-08-15: 11.0M2023-08-31: 10.3M2023-09-15: 10.9M2023-09-29: 10.6M2023-10-13: 10.9M
    the 13 Oct 2023 report24 earlier reportsnormal: 2.4M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

  40. 14 Aug 2023Institutional holdings change

    saw 42 13F filers open a new position in the quarter ended 30 Jun 2023, 10× the same quarter last year.

    Same quarter last year: 4; its normal quarter is 10.

    See the evidence
    This period
    42 (the quarter ended 30 Jun 2023)
    Normal quarter (median of 8 earlier)
    10
    Typical spread (median absolute deviation)
    3.5
    How far from its usual level
    +6.2
    Same quarter last year
    4
    History used
    1,552 days
    2021-06-30: 192021-09-30: 42021-12-31: 122022-03-31: 72022-06-30: 42022-09-30: 142022-12-31: 102023-03-31: 102023-06-30: 42
    the quarter ended 30 Jun 20238 earlier quartersnormal: 10

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

Showing the newest 40 of 100 entries; narrow the window or the kind of data to see older ones.

Not listed: 247 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001501697
Ticker
XFOR
Domain
x4pharma.com
Employer name
X4 Pharmaceuticals, Inc. (1 unverified)
Hq location
MA|BOSTON|02134 (1 unverified)
Name
Arsanis, Inc., X4 Pharmaceuticals, Inc.
Uei
QFLYNM6J7HW3
  • DOL H-1B labor condition applications and PERM certifications1 data point8 Aug 2022 to 8 Aug 2022
  • SEC Form 13F institutional holdings279 data points31 Mar 2019 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)187 records27 Apr 2016 to 4 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)574 data points31 Dec 2015 to 2 Nov 2026
  • SEC Form 4 insider transactions115 records, 224 data points20 Nov 2017 to 19 Oct 2026
  • FINRA short interest (twice monthly)549 data points15 Mar 2019 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)3868 data points14 Mar 2019 to 20 Nov 2026